Literature DB >> 4017162

Pharmacokinetics and disposition of 4'-O-tetrahydropyranyladriamycin in mice by HPLC analysis.

H Iguchi, H Tone, T Ishikura, T Takeuchi, H Umezawa.   

Abstract

The plasma level of 4'-O-tetrahydropyranyladriamycin (THP) declined rapidly after IV injection to mice, with a t1/2(alpha) of 0.453 min. Only 1.2 micrograms/ml THP was detected 2 min after injection of 5 mg/kg. The drug was immediately transferred to various tissues, where the drug levels were much higher than the plasma concentration. In the lung and spleen, 8.26 and 13.6 micrograms/g THP was present, respectively, 2 h after administration. Major metabolites of THP were 13-dihydro-THP, ADM, 7-deoxyadriamycinone, and 7-deoxy-13-dihydro-adriamycinone. Only 1.12% of the dose had been recovered in the urine by 48 h after injection as THP and its metabolites, according to analysis by HPLC fluorospectroscopy. The observed disposition of THP was compared with that of adriamycin (ADM). The plasma disappearance and tissue transfer of THP were faster than those of ADM. THP levels in the spleen and lung were higher and those in the heart and liver were lower than the corresponding ADM levels. Drug levels declined more quickly in most tissues in the case of THP than of ADM. Tissue distributions after single bolus and multiple injections were also compared and discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4017162     DOI: 10.1007/bf00257523

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

1.  Adriamycin and daunorubicin disposition in the rabbit.

Authors:  N R Bachur; R C Hildebrand; R S Jaenke
Journal:  J Pharmacol Exp Ther       Date:  1974-11       Impact factor: 4.030

2.  Tetrahydropyranyl derivatives of daunomycin and adriamycin.

Authors:  H Umezawa; Y Takahashi; M Kinoshita; H Naganawa; T Masuda; M Ishizuka; K Tatsuta; T Takeuchi
Journal:  J Antibiot (Tokyo)       Date:  1979-10       Impact factor: 2.649

3.  Cytoplasmic aldo-keto reductases: a class of drug metabolizing enzymes.

Authors:  N R Bachur
Journal:  Science       Date:  1976-08-13       Impact factor: 47.728

4.  Accumulation and metabolism of new anthracycline derivatives in the heart after IV injection into mice.

Authors:  D Deprez-de Campeneere; R Baurain; A Trouet
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

5.  4'-O-tetrahydropyranyladriamycin as a potential new antitumor agent.

Authors:  T Tsuruo; H Iida; S Tsukagoshi; Y Sakurai
Journal:  Cancer Res       Date:  1982-04       Impact factor: 12.701

6.  [Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of 14C- or 3H-aclacinomycin A in mice, rats and rabbits (author's transl)].

Authors:  H Iguchi; Y Seryu; T Kiyosaki; S Hori; H Tone; T Oki
Journal:  Jpn J Antibiot       Date:  1980-02

7.  [Studies on the absorption, excretion and distribution of aclacinomycin A: absorption, excretion and distribution of aclacinomycin A in mice, rabbits and dogs by photometric assay (author's transl)].

Authors:  H Iguchi; Y Matsushita; K Ohmori; S Hirano; T Kiyosaki; S Hori; H Tone; T Oki
Journal:  Jpn J Antibiot       Date:  1980-02

8.  Fluorescence assays and pharmacokinetic studies of 4'-deoxydoxorubicin and doxorubicin in organs of mice bearing solid tumors.

Authors:  F Formelli; C Pollini; A M Casazza; A di Marco; A Mariani
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Low heart and skin toxicity of a tetrahydropyranyl derivative of adriamycin (THP-ADM) as observed by electron and light microscopy.

Authors:  D Dantchev; M Paintrand; M Hayat; C Bourut; G Mathé
Journal:  J Antibiot (Tokyo)       Date:  1979-10       Impact factor: 2.649

10.  Rapid uptake by cultured tumor cells and intracellular behavior of 4'-O-tetrahydropyranyladriamycin.

Authors:  S Kunimoto; K Miura; Y Takahashi; T Takeuchi; H Umezawa
Journal:  J Antibiot (Tokyo)       Date:  1983-03       Impact factor: 2.649

View more
  9 in total

1.  Effects of pirarubicin, an antitumor antibiotic, on the cardiovascular system.

Authors:  S Hirano; N Agata; Y Hara; H Iguchi; M Shirai; H Tone; N Urakawa
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

2.  Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin).

Authors:  M N Raber; R A Newman; K Lu; S Legha; C Gorski; R S Benjamin; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Evaluation of anthracycline cardiotoxicity with the model of isolated, perfused rat heart: comparison of new analogues versus doxorubicin.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Development of the model of rat isolated perfused heart for the evaluation of anthracycline cardiotoxicity and its circumvention.

Authors:  P Pouna; S Bonoron-Adèle; G Gouverneur; L Tariosse; P Besse; J Robert
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

5.  Pharmacokinetics of 4'-O-tetrahydropyranyladriamycin given on a weekly schedule in patients with advanced breast cancer.

Authors:  R M Mader; H Zilg; O Schlappack; G G Steger; M Baur; B Greifenberg; U Heberle; C Dittrich
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

6.  Effects of anthracycline derivatives on hepatic neoplastic nodules of Lewis lung carcinoma and colon adenocarcinoma 26.

Authors:  M Iigo; K Nishikata; Y Nakajima; A Hoshi
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

7.  Antitumoral efficacy and pharmacokinetic properties of pirarubicin upon hepatic intra-arterial injection in the rabbit V x 2 tumour model.

Authors:  M Okada; S Kudo; O Miyazaki; T Saino; H Ekimoto; H Iguchi; S Hirano; H Kuboki; H Kadosawa; T Takeuchi
Journal:  Br J Cancer       Date:  1995-03       Impact factor: 7.640

8.  Tumor-selective distribution of an active metabolite of the 9-aminoanthracycline amrubicin.

Authors:  T Noguchi; S Ichii; S Morisada; T Yamaoka; Y Yanagi
Journal:  Jpn J Cancer Res       Date:  1998-10

9.  Characteristics of the inhibitory effect of mitoxantrone and pirarubicin on lung metastases of colon carcinoma 26.

Authors:  M Iigo; M Shimamura; K Sagawa; H Tsuda
Journal:  Jpn J Cancer Res       Date:  1995-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.